iRxReminder, LLC is thrilled to announce the enrollment of its first patients in the innovative NIMH-funded study, the TDtect Diagnostic. This groundbreaking study leverages iRxReminder’s cutting-edge Internet of Things (IoT) monitoring technology and technology partner Videra’s advanced machine-learning capabilities to validate automated identification of Tardive Dyskinesia, a potentially life-threatening adverse event associated with certain medications used by mental health patients. This marks a pivotal moment in automating medication monitoring with IoT hardware and identifying adverse effects before they become irreversible.
